kynurenine has been researched along with paclitaxel in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbruzzese, JL; Ferrandina, G; Freedman, RS; Loercher, A; Melichar, B; Verschraegen, CF | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 1 |
| Bekki, K; Haarmann-Stemmann, T; Ito, T; Li, W; Matsumura, F; Sweeney, C; Vogel, CF; Vogel, H | 1 |
| Du, G; Liu, Q; Meng, X; Sun, S; Tian, J; Wang, H; Wang, W; Wu, Z; Ye, L | 1 |
4 other study(ies) available for kynurenine and paclitaxel
| Article | Year |
|---|---|
Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines.
Topics: Aminobutyrates; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Cell Division; Cisplatin; Drug Screening Assays, Antitumor; Fatty Acids; Female; HLA Antigens; Humans; Kynurenine; Lovastatin; Mevalonic Acid; Ovarian Neoplasms; Paclitaxel; Phenylacetates; Transforming Growth Factors; Tumor Cells, Cultured | 1998 |
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Letrozole; Middle Aged; Nitriles; Paclitaxel; Triazoles; Tryptophan | 2010 |
The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Doxorubicin; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lapatinib; Paclitaxel; Polychlorinated Dibenzodioxins; Quinazolines; Receptors, Aryl Hydrocarbon; RNA, Messenger; RNA, Small Interfering; Transcription Factor RelB; Ultraviolet Rays | 2015 |
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Topics: Animals; Antineoplastic Agents; Drug Therapy, Combination; Imidazoles; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Interleukin-2; Isoindoles; Kynurenine; Male; Melanoma, Experimental; Mice, Inbred C57BL; Paclitaxel; T-Lymphocytes; Tryptophan; Tumor Burden | 2017 |